Login
Subscribe
Developing a Protocol for Generating Genetically Modified NK Cells
Developing a Protocol for Generating Genetically Modified NK Cells
Natural killer (NK) cells target infected and oncogenic cells, but are difficult to work with in vitro. Discover novel approaches to producing genetically modified NK cells for cell therapy.
Natural killer (NK) cells target infected and oncogenic cells, but are difficult to work with in vitro. Discover novel approaches to producing genetically modified NK cells for cell therapy.
chimeric antigen receptor
CAR Technology in Cancer Therapy: From CAR-T to CAR-NK
The Scientist and Sino Biological | May 10, 2023 | 4 min read
From early target discovery to preclinical development stages, researchers explore novel strategies for effective cell therapies in cancer treatment.
“Smarter” CAR T Cells Target Tumors with Precision
Natalia Mesa, PhD | Dec 16, 2022 | 5 min read
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
LabTalk Podcast - A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors
The Scientist and IsoPlexis | Apr 26, 2021 | 1 min read
Katie McKenna discusses a combination CAR T and viral therapy that kills solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Amanda Heidt | Mar 26, 2021 | 6 min read
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019 | 2 min read
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019 | 2 min read
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018 | 4 min read
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017 | 2 min read
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful.
Researchers Build a Cancer Immunotherapy Without Immune Cells
Abby Olena, PhD | Nov 13, 2017 | 3 min read
A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro.
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017 | 2 min read
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.
Another CAR-T IPO
Jef Akst | Apr 6, 2015 | 1 min read
Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.
To Each His Own
Mary Beth Aberlin | Apr 1, 2015 | 3 min read
Cancer treatment becomes more and more personal.